

Stockholm, June 18, 2009

SCN Plans to Sell Additional Shares in Scandivir

As communicated to the market in previous press releases, for example on March 30, 2009, Scandinavian Clinical Nutrition AB (SCN) has sold parts of the company's shareholding in Scandivir AB in order to strengthen the company's financial situation. With reference to the article in the Norwegian financial magazine Finansavisen today, SCN hereby clarifies that the company plans to sell additional parts or all of the company's shares in Scandivir, in line with the previously communicated strategy.

In the previous transactions, Scandivir has been valued to +/- MSEK 100. SCN has good reason to believe that future transactions can be carried out at approximately the same valuation.

For more information, please contact:

Ulf Söderberg, CEO, us@scnutrition.com, +46 708 13 22 81

Jörn Erik Aas, Chairman of the Board, jea@scnutrition.com, +47 924 99 360

Scandinavian Clinical Nutrition i Sverige AB (publ) works in R&D and distribution of clinically tested, scientifically documented products within the field of nutrition (nutraceuticals). Established in 2006, SCN maintains a product portfolio with established trademarks, such as CUUR, Coldizin, Immulina, Membra7 and Ledactin. Core competence and strategic alliances, within both R&D and sales, in combination with innovative and clinically proven products, create good conditions for profitable growth both in Sweden and internationally. The shares of SCN are traded under the ticker "SCN" on Oslo Axess (www.osloaxess.no) and NGM Equity (www.ngm.se). For more information, please visit www.scnutrition.com.